leukemia and lymphoma

Share:

(Ohio State University Medical Center) The human T-lymphotropic virus type 1, a cancer-causing retrovirus, exploits key proteins in host cells to extend the life of those cells, thereby prolonging its own survival and ability to spread, according to a new study.

The virus, which causes adult T-cell leukemia and lymphoma, produces a protein called p30 that targets two important cell proteins, one involved in DNA damage repair, the other involved in the destruction of proteins within the cell.

(John Theurer Cancer Center) A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib, the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma.

The study also provides preliminary evidence for which patients might benefit most from bortezomib.

(Lymphoma Research Foundation) Highlights from the Lymphoma Research Foundation 2009 Mantle Cell Lymphoma Consortium Scientific Workshop will be published in the March 2010 issue of Leukemia & Lymphoma.

Traditionally accessible to subscribers for period of one year, Leukemia and Lymphoma has agreed to make this report available to the public for one month -- Mantle Cell Lymphoma: Report of the 2009 MCL Consortium Workshop.

(John Theurer Cancer Center) The John Theurer Cancer Center at Hackensack University Medical Center, the nation's fourth largest cancer center, and the Leukemia and Lymphoma Society have joined forces to host the Hematological Malignancies Conference on Saturday, Sept. 26, 2009 in Hackensack, NJ.

The conference is free and attendees can receive continuing medical education credits.

(American Cancer Society) A new analysis has found that adolescents and young adults who were recently diagnosed with blood-related cancers have better long-term survival rates than those who were diagnosed in the 1980s.

(IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer) The Gamida Cell-Teva Joint Venture announced today that five prestigious cord blood transplantations centers in Spain, three in Barcelona and two in Valencia, have joined the ExCell study.

The trial is assessing the safety and efficacy of StemEx as a treatment for hematological malignancies, including leukemia and lymphoma, in a single arm, global, pivotal marketing authorization trial.